Yersinia pestis is a Gram-negative bacterium, and the causative agent of bubonic plague and pneumonic plague. Because of its potential use as a biological warfare weapon, the plague bacterium has been placed on the list of category A select agents. The dynamics of pneumonic infection following aerosolization of the highly virulent Y. pestis CO92 strain have been poorly studied; therefore, the purpose of this study was to determine the LD50 dose, bacterial dissemination, cytokine/chemokine production and tissue damage in Swiss-Webster mice over a 72 h course of infection. We exposed mice in a whole-body Madison chamber to various doses of Y. pestis CO92 aerosolized by a Collison nebulizer, and determined that the LD50 presented dose (Dp) of the bacterium in the lungs was 2.1×103 c.f.u. In a subsequent study, we infected mice at a Dp of 1.3×104 c.f.u., and harvested organs and blood at 1, 24, 48 and 72 h post-infection. Histopathological examination, in addition to measurement of bacterial dissemination and cytokine/chemokine analysis, indicated progressive tissue injury, and an increased number of animals succumbing to infection over the course of the experiment. Using these data, we were able to characterize the mouse plague model following aerosolization of Y. pestis CO92.
AndersonG. W.Jr,
LearyS. E.,
WilliamsonE. D.,
TitballR. W.,
WelkosS. L.,
WorshamP. L.,
FriedlanderA. M.1996; Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64:4580–4585
BubeckS. S.,
CantwellA. M.,
DubeP. H.2007; Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 75:697–705
CathelynJ. S.,
CrosbyS. D.,
LathemW. W.,
GoldmanW. E.,
MillerV. L.2006; RovA, a global regulator of Yersinia pestis, specifically required for bubonic plague. Proc Natl Acad Sci U S A 103:13514–13519
DollJ. M.,
ZeitzP. S.,
EttestadP.,
BucholtzA. L.,
DavisT.,
GageK.1994; Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg 51:109–114
HillJ.,
EylesJ. E.,
ElvinS. J.,
HealeyG. D.,
LukaszewskiR. A.,
TitballR. W.2006; Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 74:3068–3070
InglesbyT. V.,
DennisD. T.,
HendersonD. A.,
BartlettJ. G.,
AscherM. S.,
EitzenE.,
FineA. D.,
FriedlanderA. M.,
HauerJ.
other authors 2000; Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283:2281–2290
LathemW. W.,
CrosbyS. D.,
MillerV. L.,
GoldmanW. E.2005; Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 102:17786–17791
LathemW. W.,
PriceP. A.,
MillerV. L.,
GoldmanW. E.2007; A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315:509–513
PetersonJ. W.,
ComerJ. E.,
BazeW. B.,
NoffsingerD. M.,
WenglikowskiA.,
WalbergK. G.,
HardcastleJ.,
PawlikJ.,
BushK.other authors2007; Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 75:3414–3424
ShaJ.,
AgarS. L.,
BazeW. B.,
OlanoJ. P.,
FadlA. A.,
ErovaT. E.,
WangS.,
FoltzS. M.,
SuarezG.other authors2008; Braun lipoprotein (Lpp) contributes to the virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 76:1390–1409
SmithP. N.,
McCamishJ.,
SeelyJ.,
CookeG. M.1957; The development of pneumonic plague in mice and the effect of paralysis of respiratory cilia upon the course of infection. J Infect Dis 100:215–222
WilliamsonE. D.,
StaggA. J.,
EleyS. M.,
TaylorR.,
GreenM.,
JonesS. M.,
TitballR. W.2007; Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25:1142